We want to be sure our employees’ family members are taken care of – this includes the furry/fluffy/flying ones too! We’re excited to partner with Pet Benefits Solutions to offer comprehensive Wishbone Pet Health Insurance coverage. Pet approved!

This #MemorialDay2022, we honor our fallen heroes.

#News for #Investors and #Media. Today, we’ve announced the proposed acquisition of Affinivax. If approved, this will further strengthen our vaccine pipeline and provides access to a new, potentially disruptive technology. gsk.to/3Nfj8Gw

Today, we announced the proposed acquisition of Affinivax by GSK for a $2.1 billion upfront payment and up to $1.2 billion in potential development milestones. affinivax.com/gsk-to-acquire…

With the proposed acquisition news today, we envision that GSK's significant capabilities will enable continued advances with MAPS™ to improve upon existing vaccines and address unmet need for diseases without current immunization strategies. affinivax.com/gsk-to-acquire…

As we look ahead to an exciting future, we also look back on what the Affinivax team achieved. We built our MAPS™ platform from Boston Children’s Hospital & a pipeline of novel vaccines with our lead vaccine candidate in late-stage clinical studies. affinivax.com/gsk-to-acquire…

We’re excited to present next week at #ISPPD12 – E-poster Spotlight Talk, Session 04: Vaccine and Vaccine Trials on Monday, June 20th between 4:55-5:55PM EDT.

It’s an exciting time at Affinivax and we are focused on the steadfast growth and opportunity within our Manufacturing department. Check out these open roles! affinivax.com/careers/ #WereHiring #SimplePowerfulVaccines

Happy #Juneteenth2022! We take part in honoring this shared history which commemorates the anniversary of the news of freedom reaching enslaved Black Americans. We reflect on its significance and take stock of where we are still in the fight for equality. boston.gov/departments/sm…

Affinivax Presents Data for Enhanced Protection Against Serotype 3 in Next-Generation Pneumococcal Vaccine at the 12th International Symposium on Pneumococci and Pneumococcal Diseases affinivax.com/affinivax-pres…

At #ISPPD12, our poster presentation highlights the possibilities of engineering next generation pneumococcal vaccines. #MAPSnextgenvaccines affinivax.com/affinivax-pres…

#ISPPD12 #MAPSnextgenvaccines affinivax.com/affinivax-pres…

In honor of #PrideMonth, we are proud to introduce Brandon Hagen, Sr. Manager, Corporate Communications, in our Employee Spotlights Series for June. See what “pride” means to him and why being your authentic self should always be the standard.

We are delighted to share this publication in the journal Vaccine, detailing results from the Phase 2 clinical trial of our lead novel vaccine candidate targeting Streptococcus pneumoniae, which was developed using our proprietary MAPS™ platform. sciencedirect.com/science/articl…

Happy #PrideMonth! We celebrate Pride on this anniversary of the Stonewall Riots by reflecting on LGBTQIA+ history and striving towards greater visibility and equality. Support this community and the #NextGen Leaders here: pointfoundation.org/donate/ #PrideDay

We're pleased to share the publication of data in the journal “Vaccines.” The article highlights foundational viral vaccine POC for our MAPS™ vaccine technology platform. mdpi.com/2076-393X/10/7…

#News for #Investors and #Media. Today Affinivax joins GSK. We look forward to collaborating with this new extended team to deliver a promising new vaccine technology. More at: gsk.to/3plDPXb

#News for #Investors and #Media. Today we announced the completion of the acquisition of Affinivax. This news follows our recent acquisition of Sierra Oncology as we continue to focus on developing a strong portfolio of innovative vaccines and specialty medicines.

#AheadTogether "We are very pleased to have found the ideal home within GSK..." GSK x Affinivax

Yesterday we announced the completion of the acquisition of Affinivax – including access to the exciting MAPS technology. Check this out to learn more 👇